Sign in
CompletedPhase 1

Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with NT1

Key facts

Who runs it
Takeda Development Center Americas Inc.
Where
Italy1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 1
People taking part
16 people enrolled
Started
7 Jan 2026
Ended
21 May 2026
Type of study
Interventional
Record updated
27 November 2025

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • The participant has an ICSD-3 or ICSD-3-TR diagnosis of NT1
  • Male or female participants aged 6 to 17 years, inclusive, at the time of signing the ICF
  • The participant has a body mass index within the range 18 to 30 kg/m2
  • The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant’s CSF OX/hypocretin-1 concentration is <110 pg/mL
  • The participant is judged by the investigator to be sufficiently healthy to participate in the trial based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead ECG, and vital sign measurements performed at the screening visit and before the first dose of trial intervention
  • Parent or legal guardian – and participants old enough to understand - have expressed a willingness to participate in and complete the trial and signed and dated the ICF after getting acquainted with the participant’s information sheet, prior to beginning protocol-required procedures

Who cannot take part

  • Participant is unable to refrain from using excluded medications
  • The participant has a positive urine screen result for drugs of abuse and/or positive alcohol test result at screening or at Day -1
  • Participant has a known hypersensitivity to any component of the formulation of oveporexton or related compounds
  • Participant has a positive pregnancy test result at screening or is breastfeeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the plasma pharmacokinetic (PK) parameters of oveporexton in pediatric participants.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with narcolepsy type 1 (NT1)
Record updated
27 November 2025